BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 19928862)

  • 21. Aminothiazolomorphinans with mixed κ and μ opioid activity.
    Zhang T; Yan Z; Sromek A; Knapp BI; Scrimale T; Bidlack JM; Neumeyer JL
    J Med Chem; 2011 Mar; 54(6):1903-13. PubMed ID: 21351746
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis, opioid receptor binding, and biological activities of naltrexone-derived pyrido- and pyrimidomorphinans.
    Ananthan S; Kezar HS; Carter RL; Saini SK; Rice KC; Wells JL; Davis P; Xu H; Dersch CM; Bilsky EJ; Porreca F; Rothman RB
    J Med Chem; 1999 Sep; 42(18):3527-38. PubMed ID: 10479286
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and biological evaluation of 14-alkoxymorphinans. 18. N-substituted 14-phenylpropyloxymorphinan-6-ones with unanticipated agonist properties: extending the scope of common structure-activity relationships.
    Greiner E; Spetea M; Krassnig R; Schüllner F; Aceto M; Harris LS; Traynor JR; Woods JH; Coop A; Schmidhammer H
    J Med Chem; 2003 Apr; 46(9):1758-63. PubMed ID: 12699394
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Opioid ligands with mixed properties from substituted enantiomeric N-phenethyl-5-phenylmorphans. Synthesis of a micro-agonist delta-antagonist and delta-inverse agonists.
    Cheng K; Kim IJ; Lee MJ; Adah SA; Raymond TJ; Bilsky EJ; Aceto MD; May EL; Harris LS; Coop A; Dersch CM; Rothman RB; Jacobson AE; Rice KC
    Org Biomol Chem; 2007 Apr; 5(8):1177-1190. PubMed ID: 17406716
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Opioid binding and in vitro profiles of a series of 4-hdroxy-3-methoxyindolomorphinans. Transformation of a delta-selective ligand into a high affinity kappa-selective ligand by introduction of a 5,14-substituted bridge.
    Grundt P; Martinez-Bermejo F; Lewis JW; Husbands SM
    J Med Chem; 2003 Jul; 46(14):3174-7. PubMed ID: 12825957
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and biological evaluation of 14-alkoxymorphinans. 21. Novel 4-alkoxy and 14-phenylpropoxy derivatives of the mu opioid receptor antagonist cyprodime.
    Spetea M; Schüllner F; Moisa RC; Berzetei-Gurske IP; Schraml B; Dörfler C; Aceto MD; Harris LS; Coop A; Schmidhammer H
    J Med Chem; 2004 Jun; 47(12):3242-7. PubMed ID: 15163203
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis, opioid receptor binding, and functional activity of 5'-substituted 17-cyclopropylmethylpyrido[2',3':6,7]morphinans.
    Ananthan S; Kezar HS; Saini SK; Khare NK; Davis P; Dersch CM; Porreca F; Rothman RB
    Bioorg Med Chem Lett; 2003 Feb; 13(3):529-32. PubMed ID: 12565965
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and evaluation of novel opioid ligands with a C-homomorphinan skeleton.
    Ishikawa K; Mochizuki Y; Hirayama S; Nemoto T; Nagai K; Itoh K; Fujii H
    Bioorg Med Chem; 2016 May; 24(10):2199-205. PubMed ID: 27079125
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and SAR study of opioid receptor ligands: mono- and bis-indolomorphinans.
    Li F; Yin C; Chen J; Liu J; Xie X; Zhang A
    Chem Biol Drug Des; 2009 Oct; 74(4):335-42. PubMed ID: 19691470
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Probes for narcotic receptor mediated phenomena. 41. Unusual inverse μ-agonists and potent μ-opioid antagonists by modification of the N-substituent in enantiomeric 5-(3-hydroxyphenyl)morphans.
    Cheng K; Lee YS; Rothman RB; Dersch CM; Bittman RW; Jacobson AE; Rice KC
    J Med Chem; 2011 Feb; 54(4):957-69. PubMed ID: 21247164
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Probes for narcotic receptor mediated phenomena. Part 42: synthesis and in vitro pharmacological characterization of the N-methyl and N-phenethyl analogues of the racemic ortho-c and para-c oxide-bridged phenylmorphans.
    Kim JH; Deschamps JR; Rothman RB; Dersch CM; Folk JE; Cheng K; Jacobson AE; Rice KC
    Bioorg Med Chem; 2011 Jun; 19(11):3434-43. PubMed ID: 21570305
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mu-opioid receptor specific antagonist cyprodime: characterization by in vitro radioligand and [35S]GTPgammaS binding assays.
    Márki A; Monory K; Otvös F; Tóth G; Krassnig R; Schmidhammer H; Traynor JR; Roques BP; Maldonado R; Borsodi A
    Eur J Pharmacol; 1999 Oct; 383(2):209-14. PubMed ID: 10585536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and biological evaluation of 14-alkoxymorphinans. 11. 3-Hydroxycyprodime and analogues: opioid antagonist profile in comparison to cyprodime.
    Schmidhammer H; Jennewein HK; Krassnig R; Traynor JR; Patel D; Bell K; Froschauer G; Mattersberger K; Jachs-Ewinger C; Jura P
    J Med Chem; 1995 Aug; 38(16):3071-7. PubMed ID: 7636870
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Probes for narcotic receptor mediated phenomena. 46. N-substituted-2,3,4,9,10,10a-hexahydro-1H-1,4a-(epiminoethano)phenanthren-6- and 8-ols - carbocyclic relatives of f-oxide-bridged phenylmorphans.
    Li F; Deck JA; Dersch CM; Rothman RB; Deschamps JR; Jacobson AE; Rice KC
    Eur J Med Chem; 2012 Dec; 58():557-67. PubMed ID: 23168379
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis, Pharmacology, and Molecular Docking Studies on 6-Desoxo-N-methylmorphinans as Potent μ-Opioid Receptor Agonists.
    Dumitrascuta M; Ben Haddou T; Guerrieri E; Noha SM; Schläfer L; Schmidhammer H; Spetea M
    J Med Chem; 2017 Nov; 60(22):9407-9412. PubMed ID: 29053268
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of a 6-cyano substituent in 14-oxygenated N-methylmorphinans on opioid receptor binding and antinociceptive potency.
    Spetea M; Greiner E; Aceto MD; Harris LS; Coop A; Schmidhammer H
    J Med Chem; 2005 Jul; 48(15):5052-5. PubMed ID: 16033285
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure selectivity relationship studies of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan derivatives toward the development of the mu opioid receptor antagonists.
    Yuan Y; Elbegdorj O; Chen J; Akubathini SK; Beletskaya IO; Selley DE; Zhang Y
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5625-9. PubMed ID: 21788135
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BU74, a complex oripavine derivative with potent kappa opioid receptor agonism and delayed opioid antagonism.
    Husbands SM; Neilan CL; Broadbear J; Grundt P; Breeden S; Aceto MD; Woods JH; Lewis JW; Traynor JR
    Eur J Pharmacol; 2005 Feb; 509(2-3):117-25. PubMed ID: 15733546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure activity relationship studies of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) analogues as potent opioid receptor ligands: preliminary results on the role of electronic characteristics for affinity and function.
    Yuan Y; Elbegdorj O; Beletskaya IO; Selley DE; Zhang Y
    Bioorg Med Chem Lett; 2013 Sep; 23(18):5045-8. PubMed ID: 23948248
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, syntheses, and pharmacological characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan analogues as opioid receptor ligands.
    Yuan Y; Zaidi SA; Stevens DL; Scoggins KL; Mosier PD; Kellogg GE; Dewey WL; Selley DE; Zhang Y
    Bioorg Med Chem; 2015 Apr; 23(8):1701-15. PubMed ID: 25783191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.